Literature DB >> 10745159

Synthesis and resorption of a humoral chymotrypsin inhibitor, CI-8, by fat body of the silkworm, Bombyx mori.

K Shirai1, H Fujii, H Doira, H Iwamoto.   

Abstract

The Bombyx mori hemolymph contains up to 16 chymotrypsin inhibitors (CIs). The present in vitro culture of tissues in Grace's medium indicated that CI-8, which belongs to the largest molecular-size group of CIs with sugar moiety, is synthesized in the fat body and secreted from it during the feeding period. When the fat body from other strain which synthesizes an allelic component (CI-7) instead of CI-8 was incubated in vitro in hemolymph from the strain which has CI-8, the fat body was found to receive CI-8. Thus it was concluded that CI-8, once secreted into the hemolymph, was again sequestered into the fat body after the onset of spinning. Protein granules isolated from the pupal fat body were shown to contain CI-8, indicating that the sequestered CI-8 is present in the protein granules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10745159     DOI: 10.1016/s0965-1748(00)00003-5

Source DB:  PubMed          Journal:  Insect Biochem Mol Biol        ISSN: 0965-1748            Impact factor:   4.714


  4 in total

1.  Comparative analysis of proteome maps of silkworm hemolymph during different developmental stages.

Authors:  Yong Hou; Yong Zou; Fei Wang; Jing Gong; Xiaowu Zhong; Qingyou Xia; Ping Zhao
Journal:  Proteome Sci       Date:  2010-09-08       Impact factor: 2.480

2.  Protection against autoimmune diabetes by silkworm-produced GFP-tagged CTB-insulin fusion protein.

Authors:  Qiaohong Meng; Wenfeng Wang; Xiaowen Shi; Yongfeng Jin; Yaozhou Zhang
Journal:  Clin Dev Immunol       Date:  2011-06-06

3.  Structure-function relationship of SW-AT-1, a serpin-type protease inhibitor in silkworm.

Authors:  Cheng Liu; Yue Han; Xi Chen; Wei Zhang
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

4.  Bioavailability of orally administered rhGM-CSF: a single-dose, randomized, open-label, two-period crossover trial.

Authors:  Wenping Zhang; Zhengbing Lv; Zuoming Nie; Guogang Chen; Jian Chen; Qing Sheng; Wei Yu; Yongfeng Jin; Xiangfu Wu; Yaozhou Zhang
Journal:  PLoS One       Date:  2009-05-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.